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Targeted temperature management (TTM) of 32–34 C has
been the standard treatment for out-of-hospital cardiac arrest
since clinical trials in 2002 showed beneﬁts to survival and neu-
rological outcome. Recently, this treatment has been challenged
by another clinical trial showing no difference in outcome
between TTM of 33 C and 36 C. This protocol describes the
methodology for a meta-analysis detailing temperature-reducing
interventions to treat global ischaemia in animal models. By
combining relevant data sets in the literature, we will explore
the experimental evidence for TTM. Our aims are to explain
possible translational gaps and provide methodological consid-
erations for future experimental research and clinical trials.
Keywords: temperature management, hypothermia, cardiac arrest, global ischaemia, meta-analysis, animals
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Project Stage at Time of Protocol Submission for
Peer-Reviewed Publication
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Preliminary searches Yes Yes
Abstract screening using checklist Yes No
Full-text review of included abstracts No No
Data extraction from included papers No No
Data analysis No No
Manuscript writing No No
Research Question
B A C K G R O U N D
In Europe, attempted resuscitation in out-of-hospital car-
diac arrest is estimated to have an incidence close to
40 per 100,000 inhabitants per year.1 It is a severe medi-
cal condition with high mortality rates, and survivors fre-
quently suffer neurological deﬁcit.2 Immediately following
the onset of cardiac arrest, that is, global brain ischaemia,
energy depletion in the brain tissue leads to a severe fail-
ure of cellular homeostasis, with subsequent cell death
and inﬂammation in the brain. Experimental animal mod-
els have shown that the body temperature has a large
effect on the extent of brain damage that develops fol-
lowing global ischaemia.3–7 Hyperthermia is associated
with increased damage,4,8,9 whilst hypothermia has a
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protective effect in several injury models.3,5,7 In 2002,
two landmark randomized clinical trials testing the effects
of induced hypothermia in patients with cardiac arrest
were published.10,11 The studies showed improved neu-
rological function10,11 and increased survival10 in patients
cooled to 33 C for 12–24 hours compared to patients
with no hypothermia treatment. These studies, together
with a Cochrane review,12 have had a major impact on
the international guidelines. Since 2003, therapeutic hypo-
thermia has been the recommended treatment for
patients who regain circulation after cardiac arrest but
remain in a coma.13 However, a third clinical trial has
recently challenged the concept of therapeutic hypother-
mia. The targeted temperature management (TTM) trial
was conducted to increase the evidence base for the con-
cept of temperature regulation post-cardiac arrest and to
help determine the optimal target temperature in this
patient population. The TTM trial included a large cohort
of cardiac arrest patients (n = 939) and found no beneﬁt
from hypothermia at 33 C as compared to controlled
temperature at 36 C for the following parameters:
survival,14 detailed neurological outcome15 or release of
neuron-speciﬁc enolase.16 In addition, the THAPCA-OH
trial reported that hypothermia at 33 C after cardiac
arrest in children, compared with normothermia at 36.8
C, did not confer any signiﬁcant beneﬁt in survival, with
good functional outcome at 1 year.17 Another meta-
analysis on clinical trials also questions the supporting
evidence for induced hypothermia after cardiac arrest,
ﬁnding that the quality of evidence was low in contrast to
previous Cochrane reviews.18 Importantly, the European
Resuscitation Council (ERC) guidelines published in
October 2015 have updated previous recommendations
on post-resuscitation care to include an option for a con-
stant target temperature between 32 C and 36 C.19
Furthermore, the terms TTM or temperature control
rather than therapeutic hypothermia are recommended.
To date, there is no preclinical meta-analysis investigating
the effects of temperature reduction in relation to global
ischaemia. Overall, the authors hope to explain possible
translational gaps between animal and patient models,
with the aim of informing methodological considerations
for future experimental research and clinical trials.
R E S E A R C H Q U E S T I O N
What are the effects of temperature reduction in animal
models of cardiac arrest on neurobehavioural outcome,
histological outcome and mortality?
Objectives
1. To assess the quality of individual studies investigat-
ing temperature reduction in animal models of car-
diac arrest.
2. To assess the efﬁcacy (reported as histological out-
come, neurobehavioural outcome or mortality) of
temperature reduction in animal models of cardiac
arrest and the impact of study design factors.
3. To assess the range of supporting evidence using a
modiﬁed Stroke Therapy Academic Industry Round-
table (STAIR) criteria.
With the results from 1–3, the authors aim to explore
and discuss possible:
• Translational gaps in the available data on the effect
of temperature reduction in animal models of car-
diac arrest.
• Sources of bias and sources of heterogeneity in ani-
mal studies.
Inclusion and exclusion criteria
I N C L U S I O N
– A normothermic control group*.
– Induction of global ischaemia in the brain of an
adult**, living non-human animal (mammal).
– Investigation of reduction of temperature in relation
to global ischaemia
AND
Reporting of:
− Histological outcome assessment of neuronal cell
death/injury in brain tissues***
OR
− Neurobehavioural assessment of outcome
OR
– Mortality assessment of the temperature reduction
* Other control groups will be accepted. Please see
“Data analysis plan ! Quantitative ! Stratiﬁca-
tions” for a pre-deﬁned priority list for extraction.
** Animals assumed adult unless manuscript says it is
modelling neonatal responses. Age will be recorded if
it is given.
*** To avoid bias, an experienced preclinical
researcher (TD) will evaluate the validity of staining
protocols for determining neuronal cell death/injury
blinded to the outcomes. Validity will be assessed based
on the choice of stain(s) and the choice of structure(s)
evaluated. This will include protocols with appropriate
staining for neuronal cell death/injury and appropriate
structure and exclude protocols evaluating non-speciﬁc
cell distress or glial activity. TD may consult TC if there
is uncertainty about the validity of staining.
E X C L U S I O N
– Use of historical controls.
– Temperature reduction is induced
pharmacologically.
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– Cooling/heating was used only to prevent spontane-
ous temperature change without a corresponding con-
trol group.
– Data could not be used for meta-analysis, for exam-
ple, no information on group size or variance.
– Studies using animals treated with therapies adjuvant
to the temperature reduction will be excluded, but
where it is possible to extract data for a temperature
reduction group without adjuvant therapy and a control
group without adjuvant therapy, these will be included.
– The study researches the beneﬁts of temperature
reduction to treat newborns.
– Studies exploring either deep hypothermic circula-
tory arrest or cardiopulmonary bypass together with
temperature reduction are excluded if they do not spe-
ciﬁcally explore these as treatments of cardiac arrest.
Search Strategy
Embase & PubMed were searched with no restriction on
time of publication or language.
Rationale for search strategy: It was considered
unlikely that a study fulﬁlling the speciﬁed inclusion cri-
teria would not contain 1) a synonym to cardiac arrest
or ischaemia (broad search), 2) a synonym to hypother-
mia or temperature reduction (in title or abstract) and 3)
a synonym to the brain or its structures (broad search).
Search strategy for PubMed:
(cardiac arrest OR circulatory arrest OR ischemia OR
ischaemia OR hypoxia OR anoxia OR infarct OR infarction OR
asystole OR resuscitation) AND (hypothermia[Title/Abstract]
OR hyperthermia[Title/Abstract] OR normothermia[Title/
Abstract] OR temperature[Title/Abstract] OR thermoregula-
tory[Title/Abstract] OR thermoregulation[Title/Abstract] OR
chill therapy[Title/Abstract] OR cooling[Title/Abstract] OR cry-
otherapy[Title/Abstract]) AND (brain OR hippocampus OR
thalamus OR striatum OR cortex OR neuroprotecti* OR cere-
bral OR cerebrum OR neuron OR neuronal)
The entire string was pasted into the search ﬁeld.
Search strategy for Embase:
(’cardiac arrest’ OR ’circulatory arrest’ OR ischemia OR
ischaemia OR hypoxia OR anoxia OR infarct OR infarction OR
asystole OR resuscitation) AND (’hypothermia’:ab,ti OR
’hyperthermia’:ab,ti OR ’normothermia’:ab,ti OR ’temperature’:
ab,ti OR ’thermoregulatory’:ab,ti OR ’thermoregulation’:ab,ti
OR ’chill therapy’:ab,ti OR ’cooling’:ab,ti OR ’cryotherapy’:ab,ti)
AND (brain OR hippocampus OR thalamus OR striatum OR
cortex OR neuroprotecti* OR cerebral OR cerebrum OR neu-
ron OR neuronal)
The entire string was pasted into the search ﬁeld with
the setting “search as broadly as possible”.
The search strategy was discussed with a librarian.
Multiple variations of both synonyms and block construc-
tions were tested before arriving at the ﬁnal search
strategy.
Data Collection Processes
Articles from the Embase and PubMed searches will be
entered into EndNote X7 software. The EndNote library
will be exported to CAMARADES software, which will be
used for reviewing abstracts and full-text articles. Dupli-
cate articles will be removed both automatically (using
EndNote function “Remove duplicates”, author-year-title-
reference type) and manually as the same article may be
referenced differently between Embase and PubMed.
Independent reviewers will screen for relevant articles
looking at title and abstract; each abstract will be screened
by two independent reviewers. HO, GT and HW are pri-
marily responsible for the screening. These lists will be
merged and included articles will be reviewed in full text.
Full-text review will be performed independently by two
independent reviewers (HO and GT). Articles not meet-
ing all inclusion criteria or fulﬁlling one or more exclusion
criteria will be excluded. Reason for exclusion will be
noted. Discrepancies between the three reviewers
regarding inclusion/exclusion of full-text articles will be
solved by a further review by one of three additional
reviewers (TD, NN or JR), and, if necessary, a consensus
discussion will follow. A ﬂow diagram of included and
excluded studies at each stage will be presented in
accordance with PRISMA guidelines.20 A hand search of
the reference lists in the included articles will be per-
formed, looking for articles investigating temperature
reduction in relation to global ischaemia. As a ﬁnal com-
plement to the database search, reviews on the topic will
be searched for relevant original articles; this will be at
the discretion of senior investigators. The database search
will be updated towards the end of the project to allow
for newly published articles to be included, if applicable.
All included articles will be assessed qualitatively, quanti-
tatively and with a modiﬁed STAIR criteria. Data extraction
will be performed independently by HO and
GT. Disagreements will be solved by discussion, with the
help of TD if necessary. Aside from publication ID, author
surname and initials, journal and year of publication, qualita-
tive, quantitative and modiﬁed STAIR-criteria data will be
extracted in a pre-deﬁned data extraction sheet (see
below). Regarding quantitative data, several stratiﬁcations
will be recorded (see below). If data are only presented in
graphical form, then computerized ruler software will be
used to measure graphs (FlexRuler 2.3, DropFrame). If data
are incomplete, we will endeavour to contact the authors.
Data Analysis Plan
Q U A L I T A T I V E
Individual studies will be checked using eight criteria out-
lined below that were derived from multiple sources—
the CAMARADES quality checklist,21 the checklist for
assessing quality in studies researching the effects of
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hypothermia in focal ischaemia models by van der Worp
et al.22 and one additional criteria, number ﬁve.
1. Publication in a peer-reviewed journal.
2. Randomization to treatment or control.
3. Blinded induction of ischaemia (i.e. concealment of
treatment group allocation at time of induction of
ischaemia).
4. Blinded assessment of outcome.
5. Statement of inclusion and exclusion of animals
from the study.
6. Sample size calculation.
7. Statement of compliance with regulatory
requirements.
8. Statement regarding possible conﬂicts of interest.
We will count the number of checklist items scored by
each publication. If there is any doubt whether a study
fulﬁls a certain criteria, no points will be given. Note that
this is not an ordinal score but rather a number of check-
list items scored.
Q U A N T I T A T I V E
We plan to:
• Use a random effects model as we expect great
inter-study heterogeneity.
• Use an I-square to measure heterogeneity for the
overall estimate of each outcome.
• Set a lower limit of 10 publications to perform the
meta-analysis.
Publication bias will be measured with funnel plot,
Egger regression and trim and ﬁll.
CAMARADES software will be used for data analysis.
Effect sizes
Our primary outcome is neurobehavioural outcome; his-
tological outcome and mortality are secondary. If more
than one histological outcome or more than one beha-
vioural outcome is reported from the same cohort of
animals, we will summarize these using ﬁxed-effects
meta-analysis to provide a summary estimate of histologi-
cal or behavioural outcome for that cohort. In each
study, the number of animals per group, mean outcome
and standard error or standard deviation for both con-
trol and treatment group will be extracted. When a single
control group serves multiple treatment groups, the con-
trol group will be divided by the number of treatment
groups that are included in the meta-analysis.23 If out-
come is measured serially (behaviour, histology, mortal-
ity), then the ﬁnal measure will be extracted for meta-
analysis. Ordinal data will be analysed as continuous vari-
ables for the purpose of the meta-analysis.
For neurobehavioural and histological outcome, it is
unlikely that we can infer what a “normal” animal would
score; therefore, we will use standardized mean differ-
ence (SMD) and not normalized mean difference
(NMD).23 For mortality, we will use odds ratio.
Stratiﬁcations
The following variables, and their effect on outcome, will
be recorded from each study:
The study design will be made up of 16 items: temperature
reduction (8 items); ischaemia (2 items); and other (6 items).
Temperature reduction (8 items):
– Timing of temperature reduction (pre-, intra-, post-
ischaemia).
– Time to treatment (pre-treatment, minutes post-
ischaemia).
– Method of inducing temperature reduction (intra-
or extracorporeal or permissive).
– Depth of temperature reduction (temperature
measured closest to brain).
– Duration of temperature reduction (start of temper-
ature reduction deﬁned as start of cooling and end of
temperature reduction deﬁned as end of cooling).
– Rate of re-warming (degrees/hour; start of re-
warming deﬁned as end of cooling and end of re-
warming deﬁned as the point when normothermia is
reached or alternatively when re-warming is actively
ended; temperature difference is deﬁned as nor-
mothermia minus target temperature).
– Method of re-warming (intra- or extracorporeal or
spontaneous).
– Method of controlling temperature in the control
group (temperature management—normothermia or
hyperthermia or no intervention*).
* See below
Ischaemia (2 items):
– Model of global ischaemia (selective arrest of cere-
bral circulation, that is 2-vessel occlusion, 4-vessel
occlusion or cardiac arrest by cardioplegic agents,
exsanguination, asphyxia etc.).
– Duration of ischaemia.
Other (6 items):
– Time to outcome assessment (neurobehaviour, his-
tology, mortality).
– Species.
– Strain.
– Sex.
– Comorbid animals (diabetic, aged, hypertensive).
– Choice of anaesthetic (see Appendix 1).
Study quality (1 + 4 = 5 items, quality checklist items
numbers 2, 3, 4 + 5):
– Total study quality (according to quality checklist).
– The speciﬁc components of the quality checklist.
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Stratiﬁcations are divided into two domains: study
design and quality. These stratiﬁcations will be presented
in a forest plot with point estimates and 99% (quality)
and 99.69% (design) conﬁdence intervals.
We will measure the signiﬁcance of differences
between n groups by partitioning heterogeneity and by
using Chi-square test, n-1 df. To allow for multiple com-
parisons, we will set a signiﬁcance level at p < 0.01 for
the quality domain (n = 5) and p < 0.0031 for the design
domain (n = 16); the p values were arrived at using the
Holm–Bonferroni correction. As we use the statistically
more conservative SMD, we will partition heterogeneity
for balance instead of using the more conservative meta-
regression.23 For continuous variables, we will divide
these into quartiles for partitioning of heterogeneity.
If a study uses more than one control (e.g. induced
hypothermia vs. induced hyperthermia vs. induced nor-
mothermia), we will choose to extract the comparison(s)
according to a pre-deﬁned list of priority:
1. Induced hypothermia versus induced normothermia.
2. Induced hypothermia versus no intervention*.
3. Induced hypothermia versus induced hyperthermia**.
4. Permissive hypothermia versus induced normo-
thermia.
5. Permissive hypothermia versus induced hyper-
thermia.
* No intervention being either a) animals are allowed
to spontaneously remain at normothermia after global
ischaemia or b) animals are allowed to spontaneously
increase their temperature after global ischaemia or c)
animals are allowed to spontaneously decrease their
temperature after global ischaemia or d) unknown.
One experiment cannot contribute two different state-
ments about the same intervention (e.g. in the same
study, induced 30 C vs. induced 37 C would be
extracted with greater priority than induced 30 C
vs. induced 40 C).
** The comparison of induced hypothermia versus
induced hyperthermia is included as we anticipate that
some studies may use this to mimic the clinical sce-
nario of post-ischaemic fever. Therefore, we believe
that this comparison reﬂects our primary research
question.
P R E - S P E C I F I E D S E N S I T I V I T Y A N A L Y S I S
We will perform sensitivity analysis if more than 150 out-
comes are reported; where NMD calculation of effect
sizes is feasible, we will perform a sensitivity analysis using
NMD with meta-regression to explore the signiﬁcance of
differences between groups of studies. During the review
process, we also anticipate identifying issues regarding
suitability for sensitivity analysis—due to study variations
that we cannot anticipate at the protocol stage.
M O D I F I E D S T A I R E V A L U A T I O N
We will use modiﬁed STAIR criteria to assess the scope
of testing in the included studies, thus elucidating the pre-
clinical evidence. This modiﬁed STAIR criteria is similar
to the one constructed by O’Collins et al. to evaluate
neuroprotective drugs in models of focal ischaemia.24,25
We make a few departures from the original STAIR
recommendations; we do not demand measures concern-
ing quality control (randomization and blinding as these
relate to quality within individual studies, and our objec-
tive focuses on a cohort of studies). Some of the items in
the study by O’Collins et al. are not applicable to our
study, and we also added one item, a global ischaemia
model.
A clinically relevant temperature reduction will always
have a speciﬁc combination of time to treatment, depth
and duration. We will construct three matrixes
(<2 hours time to treatment, between 2 and 6 hours,
>6 hours), each with three durations and depths. Note
that this allows for one study to contribute with more
than one combination if it evaluates different depths,
durations or timings of temperature reduction. Other
combinations of timing (pre- and intra-ischaemic) are
possible and will be recorded but not shown in the form
of a matrix. An example is given below (see Figure 1).
The least temperature reduction from normothermia
that we record will be regarded as the upper limit of
depth.
The modiﬁed STAIR criteria consist of the following:
1. Laboratory setting—Combination tested in two or
more laboratories*.
2. Animal species—Combination tested in rodents and
gyrencephalic species.
3. Health of animals—Combination used in comorbid
animals**.
4. Sex of animals—Combination tested in male and
female animals.
5. Outcome measures—Combination evaluated with
both histology and behaviour.
6. Long-term effect—Combination has evaluated long-
term outcome (either histology, mortality or beha-
viour, 4 weeks or more after ischaemia).
7. Route of delivery—Combination tested with two
or more methods of temperature reduction (e.-
g. intravascular cooling, extracorporeal cool-
ing etc.).
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8. Global ischaemia model—Combination tested in
two or more models of global ischaemia where at
least one model of global ischaemia is accomplished
by induced cardiac arrest
* By different investigators AND in separate
laboratories.
** Diabetic, aged, hypertensive.
For each publication, we will count the number of
checklist items scored. If there is any doubt whether a
combination fulﬁls a certain criterion, no points will be
given. Note that this is not an ordinal score but rather a
number of checklist items scored.
NB Draft only. Temperature ranges in the three cate-
gories may be varied during the full-text review and data
extraction stages, as applicable.
M I S S I N G D A T A
Qualitative
If an article does not mention a qualitative feature in our
data extraction sheet, it will either be presumed not to
have been performed (e.g. no mention of randomization
will be interpreted as if it was not performed) or consid-
ered unknown (e.g. no mention of the sex of the ani-
mal used).
Quantitative
If an article does not mention a quantitative feature in
our data extraction sheet, it will be considered unknown
and excluded from that analysis.
Figure 1. Each box, that is, a combination, can get a modiﬁed STAIR score from zero to eight points. If target temperature is
presented as XX degrees +/− Y degrees, XX will be used as depth of intervention. If duration of intervention is presented as XX
min +/− Y min, XX will be used as duration, and the same applies to time to treatment.
Data Extraction Sheet
NB Draft only. Further extraction ﬁelds may be added during the full-text review and data extraction stages, as
applicable.
Items Study 1 Study 2 Etc
Publication ID
Name of principal author/investigator
Year of publication
Journal
Quality checklist
Publication in a peer-reviewed journal
Randomization to treatment or control (description)
Blinded induction of ischaemia (description)
Blinded assessment of outcome (description)
Statement of inclusion and exclusion of animals from the study (and number of animals included/
excluded and for what reason)
Sample size calculation
Statement of compliance with regulatory requirements
Statement regarding possible conﬂicts of interest
Outcomes
Number of animals per group (sham, control and intervention)
Number of groups
Mean outcome and standard deviation (histology, neurobehaviour and mortality)
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Method of neurobehavioural evaluation (description)
Method of histological evaluation (description)
Stratiﬁcations
Timing of temperature management (pre-, intra-, post-ischaemia)
Time to treatment (post-ischaemia)
Method of inducing temperature reduction (intra- or extracorporeal or permissive)
Depth of temperature reduction (temperature measured closest to brain)
Duration of temperature reduction (start of temperature reduction deﬁned as start of cooling and end
of temperature reduction deﬁned as end of cooling)
Rate of re-warming (degrees/hour; start deﬁned as end of cooling and end of re-warming deﬁned as the
point when normothermia is reached or alternatively when re-warming is actively ended; temperature
difference is deﬁned as normothermia minus target temperature)
Method of re-warming (intra- or extracorporeal or spontaneous)
Method of controlling temperature in the control group (temperature management—normothermia or
hyperthermia or no intervention*)
Model of global ischaemia (selective arrest of cerebral circulation, e.g. 2-vessel occlusion, 4-vessel
occlusion or cardiac arrest by cardioplegic agents, exsanguination, asphyxia etc.)
Duration of ischaemia
Time to outcome assessment (neurobehaviour, histology, mortality)
Species
Strain
Sex
Comorbidities (diabetic, aged, hypertensive)
Choice of anaesthetic
Modiﬁed STAIR evaluation
Laboratory setting (which laboratory/investigator was primarily responsible for the study)
Intervention–Control set up (e.g. induced hypothermia vs. induced normothermia etc.)
Comparisons of intervention–control in experiment
Contribution of Authors
HO—Hilmer Olai
GT—Gustav Thornéus
HW—Hannah Watson
MM—Malcolm Macleod
HF—Hans Friberg
JR—Jonathan Rhodes
NN—Niklas Nielsen
TC—Tobias Cronberg
TD—Tomas Deierborg
The idea for the project was developed by TD, TC,
NN and HF. This protocol was written in the spring and
summer of 2015 by HO and GT, with input from HF,
NN, TC, TD, MM, JR and HW.
Screening of abstracts (independently)—primarily HO,
GT and HW.
Full-text review (independently)—HO and GT.
• Disagreements regarding inclusion/exclusion—TD,
NN and JR.
• Evaluation of histological protocols (blinded to out-
come)—TD with support from TC.
• Hand search of reference lists in included articles
and reviews (independently)—HO, GT and HW.
Data extraction (independently)—HO and GT
Data analysis—Junior and senior investigators
Write report—Junior and senior investigators
Conﬂict of Interest
The authors have declared no conﬂicts of interest for this
article.
A P P E N D I X 1
S T R A T I F I C A T I O N S ! S T U D Y D E S I G N ! C H O I C E
O F A N A E S T H E T I C
Study 1 Study 2 Etc.
Time of
Administration**
Before
During
After
Unknown*
*Unknown time of administration.
**We will make a note “W.O.” if the drug is washed out.
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